SYRESpyre Therapeutics Inc. Common Stock
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humani…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 This Stock’s Already Up Nearly 600% Over the Past Year Spyre Therapeutics (SYRE) has surged more than 565% over the past year, driven by strong technical momentum. Shares are trading at a new 3-year high. SYRE maintains a 100% “Buy” technical opinion from Barchart. Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk... | ||
 Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data? Spyre Therapeutics has delivered a very strong 3 year return while its current valuation checks suggest the stock is not cheap, which raises questions about how much of the recent optimism is already in the price. The stock has returned roughly 7x over the past 3 years, which is an unusually large move that can leave new buyers with less room for error if expectations cool. Positive Phase 2 data across key ulcerative colitis programs can support higher growth expectations, but the reliance... | ||
 Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know This disposition follows a staggering 500% one-year stock surge. | ||
 A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know This sale was executed under a pre-arranged plan as the stock posted a staggering return over 12 months. | ||
 SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses Spyre beats Q2 loss estimates as positive phase II pipeline progress and upcoming data readouts fuel investor optimism and lift the stock. | ||
IInsider Monkey | ||